Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2018 | Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses current trials of CAR T-cell products that are targeting BCMA, and their data so far. She highlights that the patient population who have received this therapy so far have been heavily pre-treated and have limited therapeutic options. Dr Lin also discusses future strategies to futher improve CAR T-cell therapy. This interview took place at the Myeloma 2018 meeting, held in San Diego, CA.